RecruitingNot Applicable

Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

United States119 participantsStarted 2022-09-22

Plain-language summary

The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation therapy called stereotactic radiosurgery (SRS).

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Healthy volunteers \[for Study Aim 1 (SA1) and Study Aim 2 (SA2)\] will be entered into the study if they meet the following criteria: * Age ≥ 18 years * Able to understand and give informed consent * No known cancer diagnosis Patients \[for Study Aim 1 (SA1)\] will be entered into the study if they meet the following criteria: * Age ≥ 18 years * Able to understand and give informed consent * At least one untreated brain metastasis \> 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist) Patients \[for Study Aim 3 (SA3)\] will be entered into the study if they meet the following criteria: * Age ≥ 18 years * Able to understand and give informed consent * At least one untreated brain metastasis \> 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist) * Planned SRS treatment Exclusion Criteria: Healthy volunteers (SA1 \& SA2) and patients (SA1 \& SA3) exclusion criteria: * Pregnant or breastfeeding women * Pre-existing medical conditions, including the likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest * Age \< 18 years

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change of Rapid chemical exchange saturation transfer (CEST) imaging with magnetic resonance fingerprinting (MRF)/CEST-MRF parameters with and without motion

Timeframe: Up to 3 years

Trial details

NCT IDNCT05559853

SponsorMemorial Sloan Kettering Cancer Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-09-22

Contact for this trial

Ouri Cohen, PhD

646-608-8259 coheno1@mskcc.org

View on ClinicalTrials.gov More Brain Metastases trials